Universitätsmedizin Rostock

Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011 (2016) Schoffer O, Schuelein S, Arand G, Arnholdt H, Baaske D, Bargou RC, Becker N, et al. Journal article Morphologische Kriterien vesikulobullöser Hauterkrankungen in der konfokalen In-vivo-Laserscanmikroskopie (2016) Samhaber KT, Buhl T, Brauns B, Hofmann L, Mitteldorf C, Seitz CS, Schoen MP, et al. Journal article 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts (2015) Jackisch C, Harbeck N, Huober J, Von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, et al. Journal article Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder (2015) Novotny V, Froehner M, May M, Protzel C, Hergenroether K, Rink M, Chun FK, et al. Journal article Inflammatory Bowel Diseases: Current Medical and Surgical Therapy (2015) Lamprecht G, Atreya R, Kreis ME, Siegmund B, Stallmach A Journal article Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015) (2015) Untch M, Harbeck N, Huober J, Von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, et al. Journal article, Review article Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (2015) Rollig C, Serve H, Huettmann A, Noppeney R, Mueller-Tidow C, Krug U, Baldus CD, et al. Journal article Overcoming the language barrier: UroEvidence translates Cochrane abstracts (2015) Schmidt S, Kunath F, Kranz J, Zengerling F, Draeger DL, Kroeger N, Krabbe LM, et al. Journal article Huge lipomatous tumor in the adductor muscle (2015) Zonnur S, Falkeis C, Ondang G, Weiner M, Maier H, Agaimy A Journal article Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+ (2014) Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Journal article